Cefuroxime PCD Pharma Franchise Company

Cafoli Lifecare offers a Cefuroxime range of 11 formulations across tablets, dry syrup and injection, manufactured in WHO-GMP certified facilities. Distributors building a complete antibiotic portfolio can secure district-wise monopoly franchise rights across this versatile cephalosporin with full promotional support.

What is Cefuroxime?

Cefuroxime is a second-generation cephalosporin antibiotic available in both oral and injectable forms. It inhibits bacterial cell-wall synthesis and offers reliable activity against common respiratory, ENT, urinary and skin pathogens, with good stability against many beta-lactamases. Reference: PubChem - Cefuroxime.

Available Forms

The Cafoli Cefuroxime portfolio includes oral Tablets (plain and with clavulanic acid), paediatric Dry Syrup, and Injection for parenteral and surgical use. Contact us for current pack presentations and combinations.

Therapeutic Applications

Cefuroxime is prescribed for respiratory tract infections, sinusitis, otitis media, urinary tract infections, skin and soft-tissue infections and surgical prophylaxis. Prescribers include physicians, ENT specialists, surgeons, paediatricians and general practitioners.

Why Cefuroxime is a High-Potential Molecule for Distributors

Cefuroxime is unusual in bridging oral and injectable therapy for the same infection, which makes it a favourite for both OPD prescribing and surgical prophylaxis. Having tablets, dry syrup and injection under one molecule lets a distributor cover clinic, paediatric and hospital demand together, giving broad and steady prescription volume.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.

References

1. PubChem: Cefuroxime
2. MedlinePlus: Cefuroxime
3. WHO Essential Medicines List - cefuroxime